(SeaPRwire) –
SEZ6 expression levels surpass those of both approved and emerging ADC targets in SCLC Across neuroendocrine carcinomas, SEZ6 expression shows a positive correlation with DLL3 expression, indicating potential for combination therapies These findings support Whitehawk’s development of the SEZ6-directed ADC, HWK-206, with an IND submission expected in mid-2026 MORRISTOWN, N.J., May 30, 2026 — Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage … Continue reading “Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026”
This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content.
Category: Top News, Daily News
SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.